How big is LENSAR, Inc.?

As of Jun 18, LENSAR, Inc. has a market capitalization of 146.31 million and reported net sales of 57.07 million with a net profit of -56.58 million over the latest four quarters.

As of Jun 18, LENSAR, Inc. has a market capitalization of 146.31 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 57.07 million, while the sum of net profit for the same period is -56.58 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 18.65 million, and the total assets amount to 66.30 million.

What does LENSAR, Inc. do?

LENSAR, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $14 million and a net loss of $27 million as of March 2025. It has a market cap of $146.31 million and key metrics indicating significant debt and negative price-to-book value.

Overview:<BR>LENSAR, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 14 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -27 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 146.31 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.96 <BR>Return on Equity: 110.75% <BR>Price to Book: -17.51<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold LENSAR, Inc.?

Is LENSAR, Inc. overvalued or undervalued?

As of November 9, 2020, LENSAR, Inc. is considered "risky" due to negative valuation metrics and overvaluation compared to peers, despite a strong year-to-date return of 38.7%.

As of 9 November 2020, LENSAR, Inc. has moved from a "does not qualify" grade to "risky." The company appears to be overvalued given its negative valuation metrics, including a Price to Book Value of -18.68 and an EV to EBITDA of -22.68. Additionally, its P/E ratio is not applicable due to the company being loss-making, which further complicates its valuation.<BR><BR>In comparison to its peers, LENSAR's EV to EBITDA ratio of -12.34 is significantly worse than Neuronetics, Inc. at -7.61 and electroCore, Inc. at -2.55, indicating a more pronounced risk in its valuation. Despite the overvaluation, LENSAR has shown strong recent performance, with a year-to-date return of 38.7%, significantly outperforming the S&P 500's 12.22% return. However, the overall financial health and valuation metrics suggest caution for potential investors.

Is LENSAR, Inc. technically bullish or bearish?

As of September 12, 2025, LENSAR, Inc. shows a mildly bullish trend with mixed technical indicators, outperforming the S&P 500 significantly over the past year with a return of 195.24% compared to 17.14%.

As of 12 September 2025, the technical trend for LENSAR, Inc. has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while the weekly MACD and KST are bearish, contrasting with the monthly indicators which are bullish. The RSI shows no signal on the weekly and is bearish on the monthly, while Bollinger Bands reflect a bearish stance weekly but bullish monthly. Dow Theory indicates a mildly bullish trend weekly but mildly bearish monthly. <BR><BR>In terms of performance, LENSAR has outperformed the S&P 500 significantly over the 1Y period with a return of 195.24% compared to 17.14%, and also shows strong YTD performance at 38.7% versus 12.22%.